“we are excited about the anticipated major depressive disorder approval later this year.”

In context

“IL-23 receptor with similar efficacy to a biologic. As a once-a-day pill, this molecule has the potential to set a new standard in the treatment of plaque psoriasis, and we look forward to sharing more in the coming months. In neuroscience, we are building on a 17-year legacy and to be the #1 company by the end of the decade. We are pushing boundaries in diseases like schizophrenia, depression and Alzheimer's, which together affect 1 in 8 people worldwide. In Q2, SPRAVATO grew 53%, delivering sustained double-digit growth and demonstrating the power of this medicine for patients living with difficult-to-treat depression. We also completed the acquisition of intracellular therapies this quarter. Intracellular CAPLYTA is approved to treat adults with schizophrenia and bipolar depression and we are excited about the anticipated major depressive disorder approval later this year. With the addition of CAPLYTA, we now have 5 neuroscience products in market across 6 approved indications and 8 treatments in late-stage development. CAPLYTA adds to Johnson & Johnson's robust lineup of therapies with $5 billion plus potential in peak year sales and further solidifies sales growth above analyst expectations through the rest of the decade. Turning to medtech and in cardiovascular, specifically, we are leaders in heart recovery circulatory restoration and electrophysiology. Cardiovascular has some of the largest unmet needs in health care and is one of the fastest-growing spaces in medicine tech. In Q2, we delivered over 22% operational sales growth over the quarter driven by new product performance in Abiomed, show with and strength in mapping in [indiscernible] Today, we'”